Compare UTG & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTG | ARQT |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.3B |
| IPO Year | N/A | 2020 |
| Metric | UTG | ARQT |
|---|---|---|
| Price | $37.08 | $29.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.83 |
| AVG Volume (30 Days) | 317.8K | ★ 2.3M |
| Earning Date | 01-01-0001 | 10-28-2025 |
| Dividend Yield | ★ 7.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 9.86 | N/A |
| Revenue | $96,107,593.00 | ★ $317,929,000.00 |
| Revenue This Year | N/A | $85.51 |
| Revenue Next Year | N/A | $30.74 |
| P/E Ratio | $3.20 | ★ N/A |
| Revenue Growth | 8.35 | ★ 129.21 |
| 52 Week Low | $25.26 | $11.13 |
| 52 Week High | $35.29 | $31.77 |
| Indicator | UTG | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 43.82 | 59.80 |
| Support Level | $37.04 | $28.95 |
| Resistance Level | $38.00 | $31.77 |
| Average True Range (ATR) | 0.71 | 1.36 |
| MACD | 0.06 | -0.14 |
| Stochastic Oscillator | 46.75 | 54.51 |
Reaves Utility Income Fund is a closed-end management investment company. The company's investment objective is to provide a high level of after-tax income and total return consisting of tax-advantaged dividend income and capital appreciation. It invests a portion of its total assets in securities of utility companies, which may include companies in the electric, gas, water, telecommunications sectors, as well as other companies engaged in other infrastructure operations.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.